Apollo Health Ventures pumps another $180M into the burgeoning race to slow aging

Nicole DeFeudis

Editor

Anti-aging research has progressed rapidly over the last several years, with Google and even Amazon billionaire Jeff Bezos buying in. But the field’s latest investments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Apollo Health Ventures pumps another $180M into the burgeoning race to slow aging

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Apol­lo Health Ven­tures pumps an­oth­er $180M in­to the bur­geon­ing race to slow ag­ing

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Apollo Health Ventures pumps another $180M into the burgeoning race to slow aging